Benralizumab improves health-related quality of life in severe eosinophilic asthma

Reuters Health - 15/01/2021 -Results of a phase-3b trial confirm and extend the efficacy of benralizumab for patients with severe eosinophilic asthma, showing early and sustained improvements in patient-reported outcomes, lung function, asthma control, and disease-specific health-related quality of life. Benralizumab (Fasenra, AstraZenecca) is an antieosinophil humanized monoclonal antibody that selectively targets the interleukin-5 receptor expressed on the surface of eosinophils. It was approved in the US in 2017 based on phase-3 studies demonstrating improvements in multiple asthma clinical outcomes, including exacerbation rate and asthma symptoms for patients with poorly controlled severe eosinophilic asthma. "The ANDHI phase 3b study increases confidence in the benralizumab mechanism of action for treating patients with severe eosinophilic asthma through further assessment of the onset and maintenance of clinical effects, benefits in health-related quali...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on 15 January, 202126 January, 2021